GO
| HSI1 | 23,094.83 | 0.00 | -- |
| HSCEI1 | 7,791.63 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-10-27 12:14:33 UBS published a research report stating that HUTCHMED (00013.HK)'s partner AstraZeneca PLC Ordinary Shares (AZN.US) released positive data from the global Phase III SAFFRON study at the 2026 European Society for Medical Oncology (ESMO) Congress. In treating non-small cell lung cancer patients with EGFR mutations and MET overexpression/amplification, among 338 patients, Tagrisso (osimertinib) combined with savolitinib extended median progression-free survival to 7.6 months, compared with 5.4 months for chemotherapy (hazard ratio 0.55), while median overall survival was extended to 17.8 months from 12.9 months (hazard ratio 0.68). The broker believes the overall survival results were stronger than those from China's SACHI study (hazard ratio 0.84), making the data competitive against other therapies. SAFFRON provides the first global Phase III head-to-head superiority evidence and is expected to support the ongoing US BLA review, with approval potentially coming in 2027. Submissions in Europe and Japan are also progressing as planned. Meanwhile, HUTCHMED (00013.HK) also announced positive results from the Phase III SANOVO study in China. The combination therapy of Tagrisso and savolitinib extended median progression-free survival to 24.9 months, compared with 13.8 months for Tagrisso monotherapy. UBS expects the data to support the company's application filing in China in the near term, and maintained its Buy rating and HKD29.5 TP on HUTCHMED (00013.HK). (gc/ad)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |